Phase 2
N=52
Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia
Schizophrenia and Disorders With Psychotic Features · Tobacco Use Disorder
Bottom Line
View on ClinicalTrials.gov: NCT00136760 ↗Enrolled (actual)
52
Serious AEs
0.0%
Results posted
Dec 2012
Primary outcome: Primary: Urinary Cotinine — 755; 1102; 1534; 1408 ng/ml
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Bupropion (Drug); Contingent reinforcement plus placebo (Drug); non-contingent reinforcement plus bupropion (Drug); Non-contingent reinforcement plus placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Brown University
- Primary completion
- Mar 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Urinary Cotinine |
755; 1102; 1534; 1408 | — |
| SECONDARY Cigarettes Smoked Per Day |
12.7; 13.9; 18.8; 21.0 | — |
Summary
There is a high prevalence of smoking among people with schizophrenia, and there are few smoking treatment programs for these smokers. The aims of this study are to investigate the separate and combined effects of bupropion and a voucher incentive program on smoking in people with schizophrenia.
Eligibility Criteria
Inclusion Criteria
Diagnosis of schizophrenia or schizoaffective disorder, smoke 20-50 cpd, clinically stable on antipsychotic and antidepressant medications
Exclusion Criteria
Pregnant/nursing women, seizure disorder, lowered seizure threshold due to other medical conditions, positive urine drug screen positive breath alcohol test, past 2 weeks use of MAO inhibitors, any form of bupropion, cimetidine, phenobarbital, phenytoin, DA agonists, anorectics, stimulants
Data sourced from ClinicalTrials.gov (NCT00136760). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.